BridgeMD
New treatment option for Psoriasis (PsO)
Official title Effect of Semaglutide in Patients With Psoriasis and Obesity
ClinicalTrials.gov ID: NCT06937060
What this study is testing
What is semaglutide?
semaglutide is an investigational medicine, given as an injectable medicine, being studied as a potential treatment for psoriasis (pso).
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Obesity is well known to be an important comorbidity of psoriasis. It gives rise to higher risk of psoriatic arthritis, more severe disease and also poorer response to biologics.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- a clinical diagnosed Psoriatic disease of at least 6 months before signing of informed consent.
- Women who are sexually active and not postmenopausal, agreement to remain abstinent or use 2 effective methods of contraception
- \>18 years of age, up to 75 years of age
- Adult with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one...
- Moderate to severe psoriasis (PASI score 5-10= moderate, \>10 = severe)
You likely can't join if
- Patients who refuse to give consent
- Contraindication to use of GLP1 RA
- History of pancreatitis
- History of MEN / MTC
- Known hypersensitivity to semaglutide or excipients in semaglutide
- Type 1 diabetes
See the full eligibility criteria
- a clinical diagnosed Psoriatic disease of at least 6 months before signing of informed consent.
- Women who are sexually active and not postmenopausal, agreement to remain abstinent or use 2 effective methods of contraception
- \>18 years of age, up to 75 years of age
- Adult with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes...
- Moderate to severe psoriasis (PASI score 5-10= moderate, \>10 = severe)
- Chinese ethnicity
- On stable dose of standard treatment
- Ability to comply with stud
- Patients who refuse to give consent
- Contraindication to use of GLP1 RA
- History of pancreatitis
- History of MEN / MTC
- Known hypersensitivity to semaglutide or excipients in semaglutide
- Type 1 diabetes
- Gallbladder disease
- Active malignancy or History of malignancy within 5 years
- Active chronic or acute infection requiring treatment with systemic antibiotics, antiviral, antiparasitic, antiprotozoal, or antifungals within 4 weeks before baseline visit
- Pregnancy or breastfeeding, people should inform their healthcare provider of a known or suspected pregnancy
- History of allergic reaction assessed as related to investigational product by the investigator
- Major psychiatric illness
- Treatment with live/ attenuated vaccine within the last 28 days prior to randomisation
- History of alcohol or substance abuse within 6 months prior to initial screening
- Patients with a history of suicidal attempts or active suicidal ideation
The study team makes the final eligibility decision.
Where it's taking place
- Hong Kong, Hong Kong
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hong Kong, Hong Kong. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.